scholarly journals A policy window and a network of global and local policy entrepreneurs: The introduction of opioid substitution therapy in Belarus

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Ararat Babayan ◽  
Caroline Schlaufer ◽  
Arrtem Uldanov

Abstract Why does a regime that is predominantly characterised by conservative ideology introduce opioid substitution therapy (OST), a liberal policy? This article applies the Multiple Streams Framework (MSF) to examine the introduction of OST in Belarus. Methodologically, the research draws on qualitative content analysis of drug policy documents and reports as well as on interviews. Results show how an increased HIV prevalence among injecting drug users opened a policy window in the problem stream. The increase in HIV cases could be used by a network of global and local policy entrepreneurs to frame OST as a public health policy instead of a drug policy measure. Findings suggest that, in nondemocratic regimes, global policy entrepreneurs can play a dominant role in introducing new policy ideas. However, the sustainability of the policy change remains questionable when acquiescence by key policymakers is lacking.

2018 ◽  
Vol 5 (11) ◽  
Author(s):  
Jason Grebely ◽  
Massimo Puoti ◽  
Heiner Wedemeyer ◽  
Curtis Cooper ◽  
Mark S Sulkowski ◽  
...  

Abstract Background We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis. Methods Data were pooled from GT1-infected patients enrolled in 12 phase II/III/IIIb clinical trials and categorized by use of OST. Patients with ongoing drug use were excluded. HCV treatment completion, treatment adherence (≥90%), sustained virologic response at post-treatment week 12 (SVR12), and adverse events were assessed. Results Of 4747 patients, 3% (n = 149) received OST. Among patients receiving OST vs those not receiving OST, 82% (n = 122) vs 52% (n = 2409) had GT1a infection; 76% (n = 113) vs 61% (n = 2792) were treatment naïve; and 17% (n = 25) vs 18% (n = 830) had cirrhosis, respectively. The proportion of patients completing HCV treatment did not differ between those receiving and not receiving OST (97% [n = 144] vs 98% [n = 4510], respectively), whereas adherence to treatment was reduced in patients receiving vs those not receiving OST (88% [n = 105] vs 97% [n = 4057], respectively). SVR12 was similar between patients receiving and not receiving OST (94% [n = 140] vs 96% [n = 4405], respectively; P = .273). Treatment was well tolerated. Conclusions Although treatment adherence was lower in patients receiving OST vs those not receiving OST, treatment completion and SVR12 were similar between groups. These data support the use of direct-acting antiviral therapies in patients receiving OST.


2017 ◽  
Vol 31 (5) ◽  
pp. 574-579 ◽  
Author(s):  
Melissa Yéléhé-Okouma ◽  
Hervé Martini ◽  
Jérémie Lemarié ◽  
Pierre Labroca ◽  
Nadine Petitpain ◽  
...  

2015 ◽  
Vol 146 ◽  
pp. e168 ◽  
Author(s):  
Sarah Larney ◽  
Natasa Gisev ◽  
Michael Farrell ◽  
Timothy Dobbins ◽  
Lucy Burns ◽  
...  

2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Simon Holliday ◽  
Parker Magin ◽  
Christopher Oldmeadow ◽  
John Attia ◽  
Janet Dunbabin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document